+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Esophageal Cancer - Epidemiology Forecast - 2034

  • PDF Icon

    Report

  • 122 Pages
  • December 2024
  • Region: Global
  • DelveInsight
  • ID: 5524674

Key Highlights

  • Esophageal cancer occurs in the esophagus - a long hollow muscular tube that transports food from the neck to the stomach. Esophageal cancer, also known as esophagus cancer, develops in the cells that line the esophagus and occurs when a malignant tumor arises in the esophagus lining.
  • Esophageal malignancies are often discovered as a result of a person’s indications or symptoms. Examinations, testing, and a biopsy (a sample of esophageal cells) will be required to confirm the diagnosis if esophageal cancer is suspected. If cancer is discovered, more tests will be performed to establish the stage of the malignancy. The gold standard for identifying esophageal cancer is Gastroscopy.
  • Histologically, there are two forms of primary esophageal cancer: squamous cell carcinoma and adenocarcinoma; small cell carcinoma is an uncommon type of esophageal cancer. These several types of cancer arise in various types of cells in the esophagus. They evolve in distinct ways, necessitating therapeutic techniques tailored to each individual.
  • The staging system most often used for esophageal cancer is the American Joint Committee on Cancer (AJCC) TNM system, which is based on three key pieces of information, that is the extent of the tumor (T), spread to nearby lymph nodes (N) and spread (metastasis) to distant sites (M).
  • The exact cause of esophageal cancer is unknown; however, it is thought to be related to abnormalities (mutations) in the DNA of esophageal cells. The DNA of esophageal cancer cells frequently shows changes in many different genes; however, it is unclear if specific gene changes can be found in all esophageal cancers.
  • Regarding the epidemiology of esophageal cancer, in 2023, it was found that Japan accounted for the highest of the total diagnosed cases of esophageal cancer in the 7MM.
  • Among the EU4 countries, the least number of diagnosed cases of esophageal cancer were found in Italy, i.e., ~2,200 cases in the year 2023. These cases are expected to increase by 2034.
  • Esophageal Cancer, a relatively uncommon cancer, has very limited information and guidance available, with few opportunities for people to share experiences. This ends up leading to a lack of awareness about the disease. Its symptoms are also often mild until the cancer advances, and symptoms can be easily confused with other illnesses and digestive problems.
The “Esophageal Cancer - Epidemiology Forecast - 2034” report delivers an in-depth understanding of Esophageal Cancer, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Esophageal Cancer Disease Understanding and Diagnostic Algorithm

Esophageal Cancer Overview

Esophageal cancer develops when cancer cells form in the esophagus, a tube-like tissue that connects the throat and stomach. The esophagus transports food from the mouth to the stomach. The cancer begins in the esophagus’s inner layer and can spread to other layers of the esophagus and other organs of the body (metastasis).

Typically, symptoms of esophageal cancer do not appear until the tumor has grown large enough to impede eating, swallowing, or digesting food. The most common symptom of esophageal cancer is difficulty swallowing, particularly a sensation that food is lodged in the throat; in some individuals, choking on food occurs. These symptoms develop with time, with greater discomfort while swallowing as the esophagus narrows due to cancer growth.

Esophageal Cancer Diagnosis

Esophageal malignancies are often discovered by indications or symptoms. Exams, testing, and a biopsy (a sample of esophageal cells) will be required to confirm the diagnosis; if cancer is identified, more tests will help establish the extent (stage). When diagnosed late, esophageal cancer has a terrible prognosis; however, if diagnosed early, curative therapy is feasible. Before symptoms cause individuals to seek medical assistance, the condition slowly advances. Effective presymptomatic screening procedures may enhance disease outcomes. Recent research has shed light on the early detection of esophageal cancer using blood testing, sophisticated endoscopic imaging, and artificial intelligence.

Esophageal Cancer Epidemiology

The Esophageal Cancer epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total diagnosed incident cases, age-specific cases, histology-specific cases, gender-specific cases, mutation-specific cases, stage-specific cases, and line wise treated cases of esophageal cancer covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2020 to 2034.
  • The total diagnosed incident cases of esophageal cancer in the US comprised ~21,000 cases in 2023 and are projected to increase by 2034 at a CAGR of 1.9%, accounting for the second-highest diagnosed incident cases in the 7MM.
  • In 2023, as per the age-specific cases, the 65 and above segment accounted for the highest number of cases of esophageal cancer. In contrast, the < 45 age group accounted for the least number of cases in the United States.
  • In the United States, ~16,000 cases of esophageal cancer were found in case of males, whereas females accounted for ~4,000 cases of esophageal cancer in 2023.
  • As per the Histology-specific incident cases of esophageal cancer, non-squamous esophageal cancer cases accounted for ~7,500 cases of esophageal cancer, whereas ~3,000 cases of squamous esophageal cancer were found in 2023 in the United Kingdom.

Scope of the Report

  • The report covers a segment of an executive summary, and a descriptive overview of Esophageal Cancer, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
  • Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and disease progression have been provided.
  • A detailed review of current challenges in establishing diagnosis and diagnosis rate is provided.

Esophageal Cancer Report Insights

  • Patient population
  • Prevalence pattern
  • Diagnosis rate
  • Country-wise epidemiology distribution

Esophageal Cancer Report Key Strengths

  • Ten-year Forecast
  • The 7MM Coverage
  • Esophageal Cancer Epidemiology Segmentation

Esophageal Cancer Report Assessment

  • Epidemiology Segmentation
  • Current Diagnostic Practices

Key Questions

Epidemiology Insights

  • What are the disease risk, burdens, and unmet needs of Esophageal Cancer? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Esophageal Cancer?
  • What is the historical and forecasted Esophageal Cancer patient pool in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
  • What is the diagnostic pattern of Esophageal Cancer?
  • Which clinical factors will affect Esophageal Cancer?
  • Which factors will affect the increase in the diagnosis of Esophageal Cancer?

Reasons to buy

  • Insights on disease burden, details regarding diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
  • To understand the change in Esophageal Cancer cases in varying geographies over the coming years.
  • Detailed overview diagnosed incident cases, age-specific cases, histology-specific cases, gender-specific cases, mutation-specific cases, stage-specific cases, and line wise treated cases of esophageal cancer is included.
  • To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the treatment-eligible patient pool.
  • Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Table of Contents

1. Key Insights2. Report Introduction
3. Esophageal Cancer Market Overview at a Glance
3.1. Patient Share (%) Distribution of Esophageal Cancer in 2020
3.2. Patient Share (%) Distribution of Esophageal Cancer in 2034
4. Executive Summary of Esophageal Cancer
5. Disease Background and Overview
5.1. Introduction
5.2. Histological Classification of Esophageal Cancer
5.3. Stage-wise Classification of Esophageal Cancer
5.4. Causes of Esophageal Cancer
5.5. Risk Factors of Esophageal Cancer
5.6. Signs and Symptoms of Esophageal Cancer
5.7. Major Mutations in Esophageal Cancer
5.8. Molecular abnormalities of EAC
5.9. Molecular abnormalities of ESCC
5.10. Diagnosis
5.11. Imaging tests for Esophageal Cancer
5.12. Diagnostic Algorithm
5.13. Endoscopy for Cancer of the Esophagus
5.14. Biopsy and Lab Tests for Cancer of the Esophagus
5.15. Blood tests
5.16. Differential Diagnosis
5.17. Diagnostic Guidelines
5.17.1. ESMO Clinical Practice Guideline for Diagnosis (2022)
5.17.2. National Guidelines for the Diagnosis of Esophageal Carcinoma 2022 in China
5.17.3. NCCN Guidelines for Esophageal Cancer (2022)
6. Epidemiology Methodology
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Total Diagnosed Incident Cases of Esophageal Cancer in the 7MM
7.4. Epidemiology Scenario in the United States
7.4.1. Total Diagnosed Incident Cases of Esophageal Cancer in the US
7.4.2. Age-specific Cases of Esophageal Cancer in the US
7.4.3. Histology-specific Cases of Esophageal Cancer in the US
7.4.4. Gender-specific Cases of Esophageal Cancer in the US
7.4.5. Mutation-specific Cases of Esophageal Cancer in the US
7.4.6. Stage-specific Cases of Esophageal Cancer in the US
7.4.7. Linewise Treated Cases of Esophageal Cancer in the US
7.5. Epidemiology Scenario in EU4 and the UK
7.5.1. Total Diagnosed Incident Cases of Esophageal Cancer in EU4 and the UK
7.5.2. Age-specific Cases of Esophageal Cancer in EU4 and the UK
7.5.3. Histology-specific Cases of Esophageal Cancer in EU4 and the UK
7.5.4. Gender-specific Cases of Esophageal Cancer in EU4 and the UK
7.5.5. Mutation-specific Cases of Esophageal Cancer in EU4 and the UK
7.5.6. Total Stage-specific Cases of Esophageal Cancer in EU4 and the UK
7.5.7. Linewise Treated cases of Esophageal Cancer in EU4 and the UK
7.6. Epidemiology Scenario in Japan
7.6.1. Total Diagnosed Incident Cases of Esophageal Cancer in Japan
7.6.2. Age-specific cases of Esophageal Cancer in Japan
7.6.3. Histology-specific Cases of Esophageal Cancer in Japan
7.6.4. Gender-specific Cases of Esophageal Cancer in Japan
7.6.5. Mutation-specific Cases of Esophageal Cancer in Japan
7.6.6. Stage-specific Cases of Esophageal Cancer in Japan
7.6.7. Linewise Treated Cases of Esophageal Cancer in Japan
8. Appendix
8.1. Bibliography
8.2. Report Methodology
9. Publisher Capabilities10. Disclaimer
List of Tables
Table 1: Summary of Esophageal Cancer Epidemiology (2020-2034)
Table 2: Key Events
Table 3: AJCC Staging of Esophageal Cancer
Table 4: Total Diagnosed Incident Cases of Esophageal Cancer in the 7MM (2020-2034)
Table 5: Total Diagnosed Incident Cases of Esophageal Cancer in the US (2020-2034)
Table 6: Age-specific Cases of Esophageal Cancer in the US (2020-2034)
Table 7: Histology-specific Cases of Esophageal Cancer in the US (2020-2034)
Table 8: Gender-specific Cases of Esophageal Cancer in the US (2020-2034)
Table 9: Mutation-specific Cases of Esophageal Cancer in the US (2020-2034)
Table 10: Stage-specific Cases of Esophageal Cancer in the US (2020-2034)
Table 11: Linewise Treated Cases of Esophageal Cancer in the US (2020-2034)
Table 12: Total Diagnosed Incident Cases of Esophageal Cancer in EU4 and the UK (2020-2034)
Table 13: Age-specific Cases of Esophageal Cancer in EU4 and the UK (2020-2034)
Table 14: Histology-specific Cases of Esophageal Cancer in EU4 and the UK (2020-2034)
Table 15: Gender-specific Cases of Esophageal Cancer in EU4 and the UK (2020-2034)
Table 16: Mutation-specific cases of Esophageal Cancer in EU4 and the UK (2020-2034)
Table 17: Total Stage-specific Cases of Esophageal Cancer in EU4 and the UK (2020-2034)
Table 18: Linewise Treated Cases of Esophageal Cancer in EU4 and the UK (2020-2034)
Table 19: Total Diagnosed Incident Cases of Esophageal Cancer in Japan (2020-2034)
Table 20: Age-specific Cases of Esophageal Cancer in Japan (2020-2034)
Table 21: Histology-specific Cases of Esophageal Cancer in Japan (2020-2034)
Table 22: Gender-specific Cases of Esophageal Cancer in Japan (2020-2034)
Table 23: Mutation-specific Cases of Esophageal Cancer in Japan (2020-2034)
Table 24: Stage-specific Cases of Esophageal Cancer in Japan (2020-2034)
Table 25: Linewise Treated Cases of Esophageal Cancer in Japan (2020-2034)
List of Figures
Figure 1: Understanding Gastroesophageal Reflux Induced Esophageal Tumorigenesis
Figure 2: Predominant Types of Primary Esophageal Cancers
Figure 3: Staging of Esophageal Cancer
Figure 4: The Risk Factors Profiles for Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma
Figure 5: Esophageal Cancer Warning Signs
Figure 6: Top Alterations in Esophageal Squamous Cell Carcinoma
Figure 7: Esophageal Cancer (Upper Endoscopy)
Figure 8: Algorithm for the Symptoms Suggestive of Esophageal Cancer
Figure 9: Imaging Differential Diagnosis
Figure 10: Esophagectomy
Figure 11: Total Diagnosed Incident Cases of Esophageal Cancer in the 7MM (2020-2034)
Figure 12: Total Diagnosed Incident Cases of Esophageal Cancer in the US (2020-2034)
Figure 13: Age-specific Cases of Esophageal Cancer in the US (2020-2034)
Figure 14: Histology-specific Cases of Esophageal Cancer in the US (2020-2034)
Figure 15: Gender-specific Cases of Esophageal Cancer in the US (2020-2034)
Figure 16: Mutation-specific Cases of Esophageal Cancer in the US (2020-2034)
Figure 17: Stage-specific Cases of Esophageal Cancer in the US (2020-2034)
Figure 18: Linewise Treated Cases of Esophageal Cancer in the US (2020-2034)
Figure 19: Total Diagnosed Incident Cases of Esophageal Cancer in EU4 and the UK (2020-2034)
Figure 20: Age-specific Cases of Esophageal Cancer in EU4 and the UK (2020-2034)
Figure 21: Histology-specific Cases of Esophageal Cancer in EU4 and the UK (2020-2034)
Figure 22: Gender-specific Cases of Esophageal Cancer in EU4 and the UK (2020-2034)
Figure 23: Mutation-specific Cases of Esophageal Cancer in EU4 and the UK (2020-2034)
Figure 24: Total Stage-specific Cases of Esophageal Cancer in EU4 and the UK (2020-2034)
Figure 25: Linewise Treated Cases of Esophageal Cancer in EU4 and the UK (2020-2034)
Figure 26: Total Diagnosed Incident Cases of Esophageal Cancer in Japan (2020-2034)
Figure 27: Age-specific Cases of Esophageal Cancer in Japan (2020-2034)
Figure 28: Histology-specific Cases of Esophageal Cancer in Japan (2020-2034)
Figure 29: Gender-specific Cases of Esophageal Cancer in Japan (2020-2034)
Figure 30: Mutation-specific Cases of Esophageal Cancer in Japan (2020-2034)
Figure 31: Stage-specific Cases of Esophageal Cancer in Japan (2020-2034)
Figure 32: Linewise Treated cases of Esophageal Cancer in Japan (2020-2034)